SERES THERAPEUTICS INC (MCRB)
US81750R1023 - Common Stock
SERES THERAPEUTICS INC
NASDAQ:MCRB (12/20/2024, 8:23:46 PM)
After market: 0.958 +0.04 (+4.64%)0.9155
-0.01 (-0.59%)
Company Profile
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 233 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The firm is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The firm's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.
Company Info
SERES THERAPEUTICS INC
101 Cambridge Park Drive
Cambridge MASSACHUSETTS 02139
P: 16179459626
CEO: Eric D. Shaff
Employees: 233
Website: https://www.serestherapeutics.com/
MCRB News
6 days ago - Seres Therapeutics, Inc.Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that...
13 days ago - Seres Therapeutics, Inc.FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream...
a month ago - Seres Therapeutics, Inc.Seres Therapeutics to Participate in Piper Sandler Healthcare ConferenceCAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that...
2 months ago - Seres Therapeutics, Inc.Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that...
3 months ago - Seres Therapeutics, Inc.Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.ATransaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple...
3 months ago - Seres Therapeutics, Inc.Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics...
MCRB Twits
Here you can normally see the latest stock twits on MCRB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
